MCTIC
VRTX icon

MacGuire Cheswick & Tuttle Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

MacGuire Cheswick & Tuttle Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$241K Hold
1,455
– – 0.05% 88
2018
Q3 		$280K Hold
1,455
– – 0.05% 88
2018
Q2 		$247K Sell
1,455
-380
-21% -$58.9K 0.05% 90
2018
Q1 		$299K Buy
+1,835
New +$300K 0.06% 92

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

MacGuire Cheswick & Tuttle Investment Counsel's VRTX Position: Q4 2018 in Review

MacGuire Cheswick & Tuttle Investment Counsel held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2018 at 1,455 shares worth $241K. The position accounts for 0.05% of the portfolio, ranked #88.

MacGuire Cheswick & Tuttle Investment Counsel first reported a position in VRTX in Q1 2018 and has held it in 4 quarters since. The position peaked at $299K in Q1 2018. 706 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

  • MacGuire Cheswick & Tuttle Investment Counsel held 1,455 shares of Vertex Pharmaceuticals worth $241K as of Q4 2018.
  • MacGuire Cheswick & Tuttle Investment Counsel left its Vertex Pharmaceuticals share count unchanged in Q4 2018.
  • Vertex Pharmaceuticals made up 0.05% of MacGuire Cheswick & Tuttle Investment Counsel's portfolio in Q4 2018, its #88 holding.
  • MacGuire Cheswick & Tuttle Investment Counsel first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 4 quarters since.
  • MacGuire Cheswick & Tuttle Investment Counsel's Vertex Pharmaceuticals position peaked at $299K in Q1 2018.
  • 706 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on MacGuire Cheswick & Tuttle Investment Counsel's 13F filing for Q4 2018, filed 11 Feb 2019.